BIOMAT Database Logo BIOMAT Database Logo

Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. 1990

P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.

Thirty-one patients with lepromatous leprosy received recombinant interleukin 2 (IL-2) intradermally in doses ranging from 10 to 30 micrograms. Before injection and at time intervals of 2-21 days thereafter, samples of peripheral blood mononuclear cells (PBMC) were obtained. Single or multiple injections (1-3) of IL-2 did not modify the total number of circulating lymphocytes or the number of T cells and the CD4/CD8 T-cell ratio. However, IL-2 had a pronounced influence on the [3H]thymidine incorporation in response to various stimuli 4-8 days after intradermal IL-2. Stimulation indices of three- to sevenfold above pre-IL-2 levels were observed with the polyclonal activator phytohaemagglutinin (PHA) and enhanced thymidine incorporation occurred in the presence of antigens to which the patients were already sensitized, such as purified protein derivative and BCG. IL-2 had no effect on the unresponsive state of lepromatous leprosy patient T cells to the antigens of Mycobacterium leprae.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients.
August 1987, The American journal of pathology,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.
July 1986, The New England journal of medicine,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences.
May 1997, Clinical and experimental dermatology,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Cutaneous responses to irritants and microbial antigens in lepromatous leprosy.
January 1974, Transactions of the St. John's Hospital Dermatological Society,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
In vitro effect of interleukin-2 on proliferative responses of peripheral blood T cells from leprosy patients.
September 1991, Yonsei medical journal,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Analysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders.
September 1995, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to Mycobacterium leprae.
August 1984, Immunological reviews,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Immunologic responses in patients with lepromatous leprosy.
June 1976, Archives of dermatology,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma.
November 1990, The Journal of experimental medicine,
P Converse, and T H Ottenhoff, and S Work Teklemariam, and G E Hancock, and M Dietz, and M Becx-Bleumink, and A Wondimu, and R Kiessling, and Z A Cohn, and G Kaplan
Peripheral-blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C.
November 1993, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!